drugset / Trial / NCT07558850
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
Recruiting
72 enrolled
The First Affiliated Hospital with Nanjing Medical University
Rui Therapeutics Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA-UCAR-T cells in patients with autoimmune diseases. 36-72 patients are planned to be enrolled in the dose-escalation trial.
Timeline
- Start
- 2026-05-10
- Primary completion
- 2028-01-10
- Completion
- 2029-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KN3601 | Cell therapy | — | — |